見出し hamburger arrow home scrollable_table

From the New Board Director

My name is Koichi Hirahata, and I have been chosen as the new director of the board at Souyukai Medical Corporation, preceded by former director Tetsuyuki Hirahata.

At UDX Hirahata Clinic, we have been placing an effort in cancer gene testing and gene treatments. In recent years we have had patients from outside Japan, mainly from other Asian regions. We wish to do our best to meet this great responsibility.

In recent years, research and development for cancer treatment has been developing very rapidly and cancer treatments will be even more diverse. Patients will be able to choose the treatment that is best for them.
Here at UDX Hirahata Clinic, our mission is to meet the needs of each and every patient and providing the best, most safe medical treatment.

We look forward to making a contribution to this mission.

Koichi Hirahata
Board Director, Soyukai Medical Corporation


From the New Clinic Director

Thank you for choosing UDX Hirahata Clinic.
I have been newly appointed as Clinic Director, taking over the position from Dr. Tetsuyuki Hirahata.

After passing the National board examinations, I trained as a surgeon and later worked as a Urologist prior to taking a position at UDX Hirahata Clinic 7 years ago to learn more about medical treatments of the future. After a brief hiatus and maternity leave, I decided to return to this clinic while studying more about Genomics and Oncology.
It would be a great honor to receive your support and guidance as you have done with Dr. Tetsuyuki Hirahata.

As Clinic Director, my mission is going back to basics while taking the next steps.
“Basics” will be reviving and reworking Dr.Tetsuyuki Hirahata’s original idea of creating tests and treatment (regeneration treatment) when this clinic was first opened. To do this, I feel that we need to build on the gene test and treatment mindset while asking ourselves why the patient needs a certain gene test or treatment.

We also want to closely capture the needs, base ourselves on what the original mission was, and be at a place where we have evolved.
Together we want this clinic to be a place where our patients are satisfied, and our staff members work with vigor and enthusiasm.

Masami Nishijima
Director, UDX Hirahata Clinic


Oncology Treatment Counseling Carried out by Director Hirahata

◆You can apply for materials on the treatment (for free) here.

We treat cancer at the source using a tumor suppressor gene designed to match the patient’s genetics.

Cancer occurs when the genes inside cells are damaged (through genetic variation).The nature of the damage (genetic variation) is different for each person.Even among lung cancer patients only, for example, the damaged genes will vary from patient to patient.

Our clinic conducts genetic diagnoses and inspects the results for cancer-related mutations based on 131 kinds of mutation manifestations.We conduct our treatments with a precise understanding of each individual patient’s genetic variations.

Cancer gene therapy (suppressor gene therapy) is a treatment that stimulates the elimination of cancer cells and the normalization of genes by injecting normalized tumor suppressor genes into the patient’s body.

Special free consultation and counseling for cancer gene therapy
Telephone reservations/inquiries 03-3258-8080
To book an appointment, please contact us at Email

Outpatient cancer treatment in just 2-4 hours.
Both patients in a pre-cancer condition and those whose cancer has begun to develop can be treated with this method.

Cancer occurs due to a breakdown or abnormality in our genes. Oncogene therapy’s greatest merit is its ability to repair this damage the gene has sustained. This treatment is effective at reducing the number of cancerous cells and lacks the diminishing returns of regular cancer treatment methods. Therefore you can expect sufficient results from repeat treatment. One side effect of the treatment is a fever lasting 1 – 2 hours. However, this fever can be more or less fully suppressed through the administration of antipyretics.


Early detection of cancer only visible on a genetic level

To detect cancer early it’s best to discover it at the stage when genetic mutations begin to build up and diagnose and treat it before cancerous cells grow and become too big. Our clinic’s multiplex cancer diagnosis system, is system that can test 131 different genes at the same time. With just a 28ml blood sample from the patient we can investigate their genetic information and provide a diagnosis, helping you prevent and treat cancer. In addition to this, the system can also estimate your risk of various types of cancer in the next 3-5 years.


平畑光一

Koichi HIRAHATA, M.D.

Physician, Board Director of Medical Association Soyukai. Received M.D. from the Faculty of Medicine at Yamagata University. Took up residency at Toho University Ohashi Hospital in Internal Medicine and Cardiovascular Medicine. Also did residency National Hospital Organization Tokyo National Hospital in Pulmonary Medicine. He then went on to gastroenterological medicine at Toho University Ohashi Medical Center and researched on pain upon endoscopic insertion and the symptoms of gastroesophageal reflux disease. He also engaged in the medical examination and treatment of general digestive system, such as gastrointestinal disease and pancreatitis. He has been the Director of Hirahata Clinic since July 2008. He is certified as Class I Information Technology Engineer by the Former Ministry of Economy,Trade and Industry as well as LPIC Level 1 certification.


Access

Address
〒101-0021 Akihabara UDX Building, 6th Floor 4-14-1 Sotokanda Chiyoda-ku, Tokyo [ GoogleMap ]
Tel:03-3258-8080
/ FAX:03-3258-8088

Access
2-minutes on foot from the Electric Town exit of JR Akihabara Station
3-minutes on foot from exit A3 of Akihabara Station on the Tsukuba Express Line
4-minutes on foot from exit 2 of Akihabara Station on the Hibiya Subway Line

[ Google Indoor View ]